文献速递眼底病与葡萄膜炎青光眼

玻璃体内缓释类固醇植入物在青光眼引流装置患者中安全有效

INTRAVITREAL SUSTAINED RELEASE STEROID IMPLANTS ARE SAFE AND EFFECTIVE IN PATIENTS WITH GLAUCOMA DRAINAGE DEVICES.
PubMed 文献 · Retina · 2025-01-01

回顾性病例系列纳入14眼(14例)既往植入青光眼引流装置(Ahmed或Baerveldt)且无葡萄膜炎、后接受地塞米松或氟轻松玻璃体内植入的患者。植入后1年平均眼压从13.5 mmHg降至11.3 mmHg(P=0.032),抗青光眼药物数无变化,黄斑中心凹厚度平均减少204 µm(P=0.001),无眼内炎发生。

要点

  • 既往青光眼引流装置眼接受玻璃体内缓释类固醇植入后1年平均眼压较术前降低(P=0.032)。
  • 术后3个月及末次随访抗青光眼药物数量与术前无显著差异。
  • 黄斑中心凹厚度平均减少204±158 µm(P=0.001),未见眼内炎。

核心结论

  • 玻璃体内类固醇植入物对既往有青光眼引流装置患者的术后黄斑囊样水肿安全有效,眼压未升高、抗青光眼滴眼液未增加。

研究设计与样本

  • 回顾性病例系列,纳入14眼(14例患者,38%为男性,94%为人工晶状体眼)既往植入青光眼引流装置(Ahmed或Baerveldt)且无葡萄膜炎、后接受地塞米松或氟轻松丙酮化合物玻璃体内植入。

主要发现

  • 植入时平均年龄64±12岁,Baerveldt占64%、Ahmed占36%,引流管位于前房57.1%、睫状体沟28.6%、平坦部14.3%。
  • Ozurdex占93%、Yutiq占7%。
  • 平均眼压术前13.5±3.4 mmHg,术后1个月11.8±3.7 mmHg,术后3个月13.3±3.6 mmHg(P=0.35),术后1年11.3±3.8 mmHg(P=0.032)。
  • 平均抗青光眼药物数量术后3个月无变化(P=1.0),末次随访较术前减少0.36种(P=0.35)。
  • 黄斑中心凹厚度平均变化为-204±158 µm(P=0.001),无眼内炎病例。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe effects of sustained-release steroid delivery devices on intraocular pressure (IOP) in eyes with glaucoma drainage devices. METHODS: Retrospective case series of eyes with steroid implants (dexamethasone or fluocinolone acetonide) and prior glaucoma drainage devices (Ahmed, Baerveldt) without uveitis. Outcomes included IOP, IOP rise, central foveal thickness, and IOP medications. RESULTS: We included 14 eyes (14 patients, 38% men, 94% pseudophakic). Mean age at steroid implantation was 64 ± 12 years. Baerveldt (64%) was more common than Ahmed (36%). Tubes were in the anterior chamber (57.1%), sulcus (28.6%), and pars plana (14.3%). Ozurdex (93%) was more common than Yutiq (7%). Mean IOP was 13.5 ± 3.4 mmHg preimplant, 11.8 ± 3.7 mmHg at month 1, 13.3 ± 3.6 mmHg at month 3 ( P = 0.35), and 11.3 ± 3.8 mmHg at 1 year ( P = 0.032). Mean antihypertensive medication was unchanged at month 3 ( P = 1.0) and -0.36 medication at last follow-up ( P = 0.35). Mean central foveal thickness change was -204 ± 158 µ m ( P = 0.001). There were no cases of endophthalmitis. CONCLUSION: Intravitreal steroid implants were safe and effective for the treatment of postsurgical CME in patients with pre-existing glaucoma drainage devices. There was no increase in IOP and no increase in antihypertensive drops.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Zhou HW, Tandias R, Lu ES, et al. INTRAVITREAL SUSTAINED RELEASE STEROID IMPLANTS ARE SAFE AND EFFECTIVE IN PATIENTS WITH GLAUCOMA DRAINAGE DEVICES. Retina. 2025. PMID: 39805140. doi:10.1097/IAE.0000000000004396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。